학술논문

Identification of biomarkers for glycaemic deterioration in type 2 diabetes
Document Type
Source
Nature Communications EXODIAB: Excellence of Diabetes Research in Sweden EpiHealth: Epidemiology for Health eSSENCE: The e-Science Collaboration MultiPark: Multidisciplinary research focused on Parkinson´s disease. 14:1-18
Subject
Mice
Animals
Male
Diabetes Mellitus
Type 2/metabolism
Blood Glucose/metabolism
Islets of Langerhans/metabolism
Insulin/metabolism
Lipids
Biomarkers/metabolism
Cell Adhesion Molecules/metabolism
Extracellular Matrix Proteins/metabolism
Medicin och hälsovetenskap
Klinisk medicin
Endokrinologi och diabetes
Medical and Health Sciences
Clinical Medicine
Endocrinology and Diabetes
Language
English
ISSN
2041-1723
Abstract
We identify biomarkers for disease progression in three type 2 diabetes cohorts encompassing 2,973 individuals across three molecular classes, metabolites, lipids and proteins. Homocitrulline, isoleucine and 2-aminoadipic acid, eight triacylglycerol species, and lowered sphingomyelin 42:2;2 levels are predictive of faster progression towards insulin requirement. Of ~1,300 proteins examined in two cohorts, levels of GDF15/MIC-1, IL-18Ra, CRELD1, NogoR, FAS, and ENPP7 are associated with faster progression, whilst SMAC/DIABLO, SPOCK1 and HEMK2 predict lower progression rates. In an external replication, proteins and lipids are associated with diabetes incidence and prevalence. NogoR/RTN4R injection improved glucose tolerance in high fat-fed male mice but impaired it in male db/db mice. High NogoR levels led to islet cell apoptosis, and IL-18R antagonised inflammatory IL-18 signalling towards nuclear factor kappa-B in vitro. This comprehensive, multi-disciplinary approach thus identifies biomarkers with potential prognostic utility, provides evidence for possible disease mechanisms, and identifies potential therapeutic avenues to slow diabetes progression.